Recent Updates
Recently added Catalysts
SUPN Positive Sentiment

Chloe Kim Teams Up with Qelbree®, the #1 Prescribed Branded Non-Stimulant ADHD Treatment*, to Help Empower People Navigating ADHD

Monday, August 31, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Chloe Kim is collaborating with Supernus to raise awareness about ADHD in adults. The initiative emphasizes the importance of recognizing symptoms that often persist from childhood into adulthood. By encouraging individuals to work with their healthcare providers, the campaign aims to promote personalized treatment plans for managing ADHD effectively.

Market Sentiment Analysis

POSITIVE FACTORS

  • Chloe Kim's partnership raises awareness for adult ADHD.
  • Focus on tailored treatment plans empowers individuals.
  • Qelbree® is recognized as the top prescribed non-stimulant treatment.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+34%
120-day peak, hindsight
Typical move
3.7%
average across 6 past catalysts
Cash runway
~231 mo
Minimal dilution risk
Lead asset
ADS-5102
Phase 3 · Multiple Sclerosis

Full Press Release Details

Chloe Kim is partnering with Supernus to highlight the importance of recognizing ADHD in adults and help empower individuals to work with their doctors to develop a tailored treatment plan. While ADHD is often associated with childhood, symptoms frequently persist into adulthood, and many people go

Frequently Asked Questions

What is the goal of Chloe Kim's partnership with Supernus?

The partnership aims to raise awareness about adult ADHD and promote tailored treatment plans.

What is Qelbree®?

Qelbree® is the top prescribed non-stimulant treatment for ADHD.

Why is ADHD awareness important for adults?

Recognizing ADHD in adults helps ensure they receive appropriate treatment and support.

How can individuals manage their ADHD symptoms?

Individuals are encouraged to work with their doctors to develop personalized treatment plans.

ShareAdd on Google
Tags: SUPN Viatris Investor Conferences Healthcare Chloe Kim Supernus Qelbree ADHD treatment non-stimulant ADHD
Last updated: Aug 31, 2026

Biotech snapshot

Cash runway
$372M liquidity · $2M/mo burn
~231 mo
Minimal dilution risk
Lead asset
ADS-5102Phase 3
Multiple Sclerosis →

Catalyst track record

+34%
best trade around SUPN's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for SUPN.

See every catalyst's timing & PoA →